AL3818 for Sarcoma, Alveolar Soft Part
This study is evaluating whether a drug may help treat sarcoma.
See full descriptionAbout the trial for Sarcoma, Alveolar Soft Part
Treatment Groups
This trial involves 6 different treatments. AL3818 is the primary treatment being studied. Participants will be divided into 3 treatment groups. Some patients will receive a placebo treatment. The treatments being tested are in Phase 3 and have had some early promising results.
About The Treatment
Eligibility
This trial is for patients born any sex aged 18 and older. You must have received 1 prior treatment for Sarcoma, Alveolar Soft Part or one of the other 6 conditions listed above. There are 10 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether AL3818 will improve 2 primary outcomes and 2 secondary outcomes in patients with Sarcoma, Alveolar Soft Part. Measurement will happen over the course of From time of randomization to the date of disease progression or death from any cause, up to 48 months.
Patient Q & A Section
Can sarcoma, alveolar soft part be cured?
The authors believe the data reported here support previous evidence for the concept that there are circumstances in which sarcoma can be cured. However, this cure may be difficult to confirm because the disease can relapse.
How many people get sarcoma, alveolar soft part a year in the United States?
A large number of people have sarcoma, alveolar soft part a year in the United States. Most patients (71%) had high grade soft tissue sarcoma and 40% had soft tissue sarcoma at the time of diagnosis, which suggests that patients with soft tissue sarcoma, specifically high grade sarcoma, are likely to be misdiagnosed at the time of diagnosis. Inadequate treatment or delayed management is one factor that contributes to the high number of deaths secondary to sarcoma, alveolar soft part a year in the United States.
What causes sarcoma, alveolar soft part?
The causes of alveolar soft part sarcomas are a more complex issue, than we suppose. In most reports about tumor morphology, we can see alveolar soft part sarcomas. Most of them occur due to radiation therapy, which is usually used for the control of local and distant neoplasms. In an attempt to eradicate the tumor cells, we can see in most cases a better prognosis and a better patient's outcome.
What are the signs of sarcoma, alveolar soft part?
We have not been able to identify the signs specific to STS/ASPS. Many general signs of cancer are present, but it remains a long time to diagnosis.
What is sarcoma, alveolar soft part?
Sarcoma, alveolar soft part is a type of cancer that mostly starts within the limbs, or soft tissues around them. The American Cancer Society estimates 5,000 new sarcoma cases in the United States, which accounts for nearly one third of all cancer cases that are diagnosed in that age group. It can be difficult to diagnose, as tumors in other areas of the body may be present concurrently. The disease is highly aggressive, with a low survival rate.
What are common treatments for sarcoma, alveolar soft part?
Bullet lesions are almost always resected, depending on size and extension of tumours. However, in most cases, there is no residual tumour on histologic examination, provided that the patient survives the initial course of chemotherapy.
How quickly does sarcoma, alveolar soft part spread?
The survival time between diagnosis and surgery has increased from a median time of 37 days to an average of 52 days. This is more than three and a halffold longer than reported by studies of the early 1970s. This increase in survival time has coincided with a decrease in mortality in sarcoma from a 10-year survival rate of 49% in 1970 to 37% in 2010. This decrease is in the range of what is commonly called improved survival.
Have there been any new discoveries for treating sarcoma, alveolar soft part?
There were no studies of new treatments for [soft tissue sarcoma](https://www.withpower.com/clinical-trials/soft-tissue-sarcoma) or alveolar soft part sarcoma in either systematic review. Although there may be new treatment options for sarcoma, alveolar soft part sarcoma, and other sarcomas, more research and clinical trials are needed.
What is the latest research for sarcoma, alveolar soft part?
For sarcoma, metastases in bone may occur in patients with advanced, bulky disease, but local control is very poor. Advanced lymphocytic sarcoma may regress on chemotherapy. For patients with localized sarcoma, local limb amputation should not be routinely prescribed, due to the risk of early malignant transformation (metaplastic changes) in high-grade tumors. If local control with limb amputation is used, the ultimate 5-year survival rate can be around 5-10%. The 5-year survival rate for patients with advanced tumors, no residual disease, and metastases in bones, is around 35-40% for limb amputation and 60% for limb conservation. These patients can benefit from new therapy.
What are the chances of developing sarcoma, alveolar soft part?
The risk and incidence rates are low for development ALPS, but a small number of cases will have sarcomas. Patients with sarcomas in the extremities have better outcomes, while patients with sarcomas elsewhere do worse. Patients who develop an ALPS may have longer terms survival after diagnosis if treated with R-CHOP, CHOP with autologous stem cell transplant, or CHOP with ASCT.
What is the average age someone gets sarcoma, alveolar soft part?
The average age at diagnosis of sarcoma and ASPS in this study was 32.3 years for women and 34.6 for men. These ages are higher than that reported in the literature. The majority of sarcomas and ASPS occur in the 30 years of age and above age range. This age group in the United States is predominantly female. The average age at diagnosis for ASPS was lower in this study at 27 years, although this result could be skewed by the small sample size.
What are the common side effects of al3818?
Al3818 is known to be efficacious in the treatment of the most common form of skin cancer, alveolar soft part sarcoma (ASPS). However, it is not expected to have any major side effects outside of those that occur in the majority of patients with ASPS. Al3818 should not be used by patients who have a history of hypersensitive reactions to al3818 or those who are allergic to any of the inactive ingredients. Al3818 should not be given to children under three years old, who should be taken to a medical professional immediately after using al3818. If these precautions cannot be heeded, medical advice should be sought immediately.